Treponema Pallidum Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033

Abstract

Treponema Pallidum Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.

The model discusses in detail the impact of COVID-19 on Treponema Pallidum Tests market for the year 2020 and beyond. Syphilis is a type of sexually transmitted disease which can lead to long-term health complications if left untreated. Treponema pallidum is the causative organism of the syphilis. The increasing prevalence of syphilis as well as growing public awareness represent major driving factors for growth of the syphilis testing market. The market is also witnessing various new syphilis diagnostic devices and testing platforms, with an increased number of product launches and regulatory approvals occurring in recent years for new and innovative products. There is also a demand for point of care (POC) tests for syphilis diagnosis, due to the time-consuming process of laboratory-based tests that can lead to treatment delays.

These diagnostic tests provide rapid results, reduce hospital stays and lead to immediate treatment decisions. Serological tests represent the most widely used form of Syphilis testing. Syphilis can cause serious complications in pregnancy and result in non-immune hydrops fetalis, intrauterine growth restriction, spontaneous abortion, preterm delivery, and perinatal death as well as serious sequelae in liveborn infected children. Screening of all women in the first trimester of pregnancy is considered a cost-effective strategy in many countries.

The Treponema Pallidum Tests include Venereal Disease Research Laboratory (VDRL), Rapid Plasma Reagin (RPR), Unheated Serum Reagin (USR), Treponema Passive Particle Agglutination (TPPA), Treponema Pallidum Hemagglutination (TPHA), Fluorescent Treponemal Antibody Absorption (FTA-ABS) and Treponema Pallidum EIA tests.

Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are:

Currently marketed Treponema Pallidum Tests and evolving competitive landscape:

• Insightful review of the key industry trends.
• Annualized total Treponema Pallidum Tests market revenue by segment and market outlooks from 2015-2033.
• Market level data on units, average selling prices and market values.

Global, Regional and Country level market specific insights:

• Qualitative market specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country specific insights on the market.
• SWOT analysis for Treponema Pallidum Tests market.
• Competitive dynamics insights and trends provided for Treponema Pallidum Tests market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

• Country specific overview of the healthcare system.
• Country specific reimbursement policies.
• Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: Becton Dickinson and Co, Abbott Laboratories, Siemens AG, Bio-Rad Laboratories Inc, H.U. Group Holdings Inc, Trinity Biotech Plc, Arlington Scientific Inc, F. Hoffmann-La Roche Ltd, Tecan Group Ltd, Revvity Inc, Cardinal Health Inc, bioMerieux SA, DiaSorin SpA, Omega Diagnostics Group Plc, Rapid Labs Ltd, Deben Diagnostics Ltd, Lorne Laboratories Ltd, Werfen Life Group SAU, Sekisui Diagnostics LLC, and others.

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.

Scope

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -

• CMO executives who must have deep understanding of the Treponema Pallidum Tests market place to make strategic planning and investment decisions.
• Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
• Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to -

• Understand the impact of COVID-19 on Treponema Pallidum Tests market.
• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving Treponema Pallidum Tests market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Treponema Pallidum Tests market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
• Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
• Track device sales in the global and country-specific Treponema Pallidum Tests market from 2015-2033.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.